Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 11/20 | 0.54 |
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | TEK | Q02763 | 3/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407368 | 0.89 | PDGFRB (0.53) | KDRPDGFRAFGFR2AURKAMET | |
| SCHEMBL22407406 | 0.88 | HTR1A (0.44) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL22407328 | 0.88 | KDR (0.50) | KDRPDGFRAFGFR2AURKAMET | |
| SCHEMBL22407425 | 0.87 | KDR (0.50) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL22407308 | 0.84 | KDR (0.47) | KDRPDGFRAFGFR2AURKAMET | |
| SCHEMBL20782866 | 0.83 | AXL (0.61) | AXLKDRPDGFRAFGFR2KIT | |
| SCHEMBL20775123 | 0.82 | FGFR2 (0.57) | KDRPDGFRAFGFR2KITAURKA | |
| SCHEMBL22407579 | 0.81 | MET (0.53) | KDRPDGFRAFGFR2MET | |
| SCHEMBL22407371 | 0.81 | KDR (0.51) | KDRPDGFRAFGFR2AURKAMET | |
| SCHEMBL14540589 | 0.79 | MET (0.55) | AXLKDRPDGFRAFGFR2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | AXL 3774/4885KDR 2584/4885PDGFRA 624/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | AXL 3774/4885KDR 2584/4885PDGFRA 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.